Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Microencapsul ; 32(6): 608-17, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26190213

RESUMEN

The aim of this research was to evaluate the potential of water-in-oil-in-water (w/o/w) and solid-in-oil-in-water (s/o/w) emulsification techniques to prepare the altered collagen type II peptide AP268-270 (ACTP)-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres to make ACTP more convenient as an rheumatoid arthritis treatment. Microspheres produced by the s/o/w method had higher drug encapsulation efficiency (69.7-79.8%) than those prepared by the w/o/w method (21.8-39.3%). In vitro drug release was influenced by the microencapsulation technique, molecular weight, and composition of the polymer. After intramuscular injection of the optimal formulation to Lewis rats, the concentration of ACTP peptide in serum reached its maximum level on day 3 and then remained nearly stable for approximately 4 weeks. In a collagen-induced arthritis rat model, a single intramuscular injection of ACTP-loaded PLGA microspheres had comparable efficacy to the intravenous injection of ACTP peptide solution once every other day.


Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Colágeno Tipo II/química , Ácido Láctico/química , Microesferas , Ácido Poliglicólico/química , Animales , Artritis Reumatoide/metabolismo , Cromatografía Líquida de Alta Presión , Sistemas de Liberación de Medicamentos , Femenino , Cinética , Microcirculación , Microscopía Electrónica de Rastreo , Peso Molecular , Tamaño de la Partícula , Péptidos/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ratas , Ratas Endogámicas Lew , Agua/química
2.
Acta Biochim Biophys Sin (Shanghai) ; 46(9): 782-91, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25098624

RESUMEN

The bacterial plasminogen-activator staphylokinase (Sak) is a promising thrombolytic agent for treating acute myocardial infarction. To effectively reduce the immunogenicity of Sak while maintaining its fibrinolytic activity, site-specific PEGylation was performed in the present study. The chemoselective cysteine PEGylation site was selected within an immunodominant region (amino acid residues 71-87) using an in silico approach. The PEGylated Sak variants prepared in this study showed a purity of >97.0%. PEGylation at Position 80 resulted in a Sak variant Sak(E80C-PEG) which has similar fibrinolytic activity and thermostability compared with the native recombinant staphylokinase (r-Sak). The immunogenicity of Sak(E80C-PEG) in guinea pigs was greatly reduced compared with the native r-Sak. Furthermore, preliminary pharmacokinetic results suggested that the plasma clearance of Sak(E80C-PEG) from the blood stream of rabbit was significantly decreased compared with that of r-Sak, resulting in a 2.8-fold increase of initial half-life and a 3.8-fold increase of systemic availability. In summary, these results demonstrated that site-specific PEGylation yielded a novel Sak variant Sak(E80C-PEG) with remarkable advantages over the unmodified Sak.


Asunto(s)
Fibrinólisis , Metaloendopeptidasas/farmacocinética , Polietilenglicoles/química , Animales , Secuencia de Bases , Cartilla de ADN , Electroforesis en Gel de Poliacrilamida , Estabilidad de Enzimas , Ensayo de Inmunoadsorción Enzimática , Cinética , Metaloendopeptidasas/inmunología , Metaloendopeptidasas/metabolismo , Plasminógeno/metabolismo , Conejos
3.
Acta Pharmacol Sin ; 33(1): 137-44, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22139004

RESUMEN

AIM: To characterize the pharmacokinetic and pharmacodynamic profiles of the recombinant human erythropoietin (rhEPO)-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres in rats. METHODS: The rhEPO-loaded microspheres were prepared using a solid-in-oil-in-water emulsion method. Pharmacokinetics and pharmacodynamics of the rhEPO-loaded microspheres were evaluated in male Sprague-Dawley rats. The serum rhEPO level was determined with ELISA. The level of anti-rhEPO antibody in the serum was measured to assess the immunogenicity of rhEPO released from the microspheres. RESULTS: rhEPO was almost completely released from the PLGA microspheres in vitro, following zero-order release kinetics over approximately 30 d. After intramuscular injection (10,000 or 30,000 IU rhEPO/kg) in the rats, the serum rhEPO concentration reached maximum levels on d 1, then decreased gradually and was maintained at nearly steady levels for approximately 4 weeks. Furthermore, the release of rhEPO from the PLGA microspheres was found to be controlled mainly by a dissolution/diffusion mechanism. A good linear correlation (R(2)=0.98) was obtained between the in vitro and in vivo release data. A single intramuscular injection of the rhEPO-loaded PLGA microspheres (10,000 or 30,000 IU rhEPO/kg) in the rats resulted in elevated hemoglobin and red blood cell concentrations for more than 28 d. Moreover, the immunogenicity of rhEPO released from the PLGA microspheres was comparable with that of the unencapsulated rhEPO. CONCLUSION: The results prove the feasibility of using the PLGA-based microspheres to deliver rhEPO for approximately 1 month.


Asunto(s)
Eritropoyetina/farmacocinética , Ácido Láctico/química , Ácido Láctico/farmacocinética , Microesferas , Ácido Poliglicólico/química , Ácido Poliglicólico/farmacocinética , Proteínas Recombinantes/farmacocinética , Animales , Emulsiones , Eritropoyetina/química , Humanos , Masculino , Tamaño de la Partícula , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/química
4.
J Microencapsul ; 28(8): 763-70, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22034953

RESUMEN

Biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres for the sustained release of low molecular weight heparin (LMWH) were prepared by a soild-in-oil-in-water (s/o/w) emulsion method. Prior to encapsulation, the LMWH micro-particles were fabricated by a modified freezing-induced phase separation method. The micro-particles were subsequently encapsulated into PLGA microspheres. Process optimization revealed that the NaCl concentration in the outer phase of s/o/w emulsion played a critical role in determining the properties of the microspheres. When the NaCl concentration increased from 0% to 5%, the encapsulation efficiency significantly increased from 51.5% to 76.8%. The initial burst release also decreased from 37.3% to 12.4%. In vitro release tests showed that LMWH released from PLGA microspheres in a sustained manner for about 14 days. Single injection of LMWH-loaded PLGA microspheres into rabbits resulted in an elevation of an anti-factor Xa activity for about 6 days. Furthermore, the integrity of the encapsulated LMWH was preserved during encapsulation process.


Asunto(s)
Anticoagulantes/administración & dosificación , Preparaciones de Acción Retardada/química , Emulsiones/química , Heparina de Bajo-Peso-Molecular/administración & dosificación , Ácido Láctico/química , Ácido Poliglicólico/química , Animales , Anticoagulantes/farmacología , Composición de Medicamentos , Factor Xa/metabolismo , Inhibidores del Factor Xa , Heparina de Bajo-Peso-Molecular/farmacología , Microesferas , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Conejos
5.
Yao Xue Xue Bao ; 45(8): 1057-63, 2010 Aug.
Artículo en Zh | MEDLINE | ID: mdl-21351596

RESUMEN

The aim of this study is to investigate the critical factor affecting the properties of PLGA microspheres fabricated by a solid-in-oil-in-water (S/O/W) emulsion technique with BSA as a model protein. Prior to encapsulation, the BSA microparticles were fabricated by a modified freezing-induced phase separation method. The microparticles were subsequently encapsulated into PLGA microspheres by S/O/W emulsion method, then Motic BA200 biological microscope, confocal laser scanning microscope, scanning electron microscope were used to observe the structure of S/O/W emulsion and PLGA microspheres. The protein content extracted or released from BSA microspheres was measured by Bradford protein assay method. It was found that NaCl added in the outer aqueous phase effectively suppressed material exchange between the inner and outer phase of S/O/W emulsion. Then, the structure and permeability of obtained microspheres were influenced. As a result, with the increase of NaCl concentration in the outer aqueous phase, the encapsulation efficiency of microspheres significantly increased from 60% to more than 85%, the burst release of microspheres reduced from 70% to 20%, and the particle size decreased from 103 microm to 62 microm. Furthermore, the rehydration of encapsulated protein was also retarded and then integrity of BSA was successfully protected during encapsulation process. In vitro release test showed that BSA released from PLGA microspheres in a sustained manner for more than 30 days.


Asunto(s)
Ácido Láctico/química , Ácido Poliglicólico/química , Albúmina Sérica Bovina/química , Cloruro de Sodio/química , Preparaciones de Acción Retardada , Composición de Medicamentos , Emulsiones/química , Ácido Láctico/administración & dosificación , Microscopía Confocal , Microscopía Electrónica de Rastreo , Microesferas , Aceites , Tamaño de la Partícula , Ácido Poliglicólico/administración & dosificación , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Albúmina Sérica Bovina/administración & dosificación , Agua
6.
Int J Nanomedicine ; 12: 6617-6632, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28924346

RESUMEN

The aim of the present work was to investigate the synergistic effect between toll-like receptor (TLR) 3 ligand polyinosinic:polycytidylic acid (pI:C) and TLR5 ligand flagellin (FLN) on immune responses induced by nasally delivered hepatitis B virus surface antigen (HBsAg). Mannan and chitosan oligosaccharide-modified, pH-responsive poly(lactic-co-glycolic acid) (MC-PLGA) microparticles (MPs) containing HBsAg, FLN, pI:C or both ligands were prepared with a double-emulsion method. In vitro uptake experiments show that cellular uptake of MC-PLGA MPs by macrophages was through energy-dependent, receptor-mediated endocytosis mechanism. After uptake of MPs by macrophages, MC-PLGA MPs existed both in the endo-some and in the cytoplasm. FLN and pI:C in solution or MP formulation could synergize to activate macrophages and induce higher pro-inflammatory cytokines interleukin (IL)-6, IL-12, interferon-γ and anti-inflammatory cytokines IL-10 compared to single TLR ligand (P<0.05). In vivo immunogenicity studies indicated that co-delivery of FLN and pI:C within MC-PLGA MPs synergistically induced higher serum anti-HBsAg IgG levels and Th1 cytokine levels compared with MC-PLGA MPs encapsulated single TLR ligand plus MPs encapsulated HBsAg (P<0.05). These results suggest that synergic TLR3 and TLR5 stimulation might be a promising novel tool for nasally delivered HBsAg.


Asunto(s)
Portadores de Fármacos/química , Flagelina/administración & dosificación , Antígenos de Superficie de la Hepatitis B/administración & dosificación , Poli I-C/administración & dosificación , Administración Intranasal , Animales , Quitosano/química , Portadores de Fármacos/administración & dosificación , Sinergismo Farmacológico , Femenino , Interferón gamma/metabolismo , Interleucina-10/metabolismo , Interleucina-12/metabolismo , Ácido Láctico/química , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Macrófagos/metabolismo , Microesferas , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ratas Sprague-Dawley
7.
Int J Pharm ; 309(1-2): 101-8, 2006 Feb 17.
Artículo en Inglés | MEDLINE | ID: mdl-16413979

RESUMEN

The aim of this study is to prepare poly(lactic-co-glycolic acid) (PLGA) microspheres containing a staphylokinase variant K35R (DGR) with purpose of preserving the protein stability during both encapsulation and drug release. DGR-loaded microspheres are fabricated using a double-emulsion solvent extraction technique. Prior to encapsulation, the effect of ultrasonication emulsification of DGR solutions with methylene chloride on protein recovery was investigated. Moderate ultrasonic treatment of aqueous DGR/dichloromethane mixtures caused approximately 84% DGR aggregation. Polyvinyl alcohol (PVA) added into aqueous DGR solutions significantly improved DGR recovery to >90%. The effects of co-encapsulated PVA and NaCl in the external aqueous phase on the characteristics of the microspheres were investigated. When 2% PVA was co-encapsulated and 2.5% NaCl was added to the external water phase, DGR encapsulation efficiency was significantly increased from 7.1% to 78.1% and DGR was distributed uniformly throughout the microspheres. In vitro release test showed that DGR was released from PLGA microspheres in a sustained manner over 15 days. A large amount of released DGR was inactive in the absence of co-encapsulated PVA. On the contrary, when 2% PVA was co-encapsulated, the released DGR was almost completely intact within 9 days. In conclusion, PLGA microspheres can be an effective carrier for DGR and form a promising depot system.


Asunto(s)
Portadores de Fármacos , Ácido Láctico/química , Metaloendopeptidasas/química , Microesferas , Ácido Poliglicólico/química , Polímeros/química , Química Farmacéutica , Preparaciones de Acción Retardada , Estabilidad de Enzimas , Excipientes/química , Cloruro de Metileno/química , Tamaño de la Partícula , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Alcohol Polivinílico/química , Desnaturalización Proteica , Solubilidad , Solventes/química , Propiedades de Superficie , Tecnología Farmacéutica/métodos , Factores de Tiempo , Ultrasonido
8.
Yao Xue Xue Bao ; 41(1): 12-8, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16683521

RESUMEN

AIM: To produce poly (lactic-co-glycolic acid) (PLGA) microspheres, containing a staphylokinase variant (K35R, DGR) with reduced immunogenecity and antiplatelet aggregation activities, which allowed the preservation of protein stability during both particle processing and drug release. METHODS: DGR-loaded microspheres were fabricated using a double emulsion-solvent evaporation technique. The effects of preparative parameters, such as stirring rate, polymer concentration, and the excipients of both internal and external aqueous phase (W2), on DGR encapsulation efficiency and microsphere characteristics were investigated. In vitro and in vivo release of DGR were conducted and the cause for instability of DGR during release was also investigated. RESULTS: Moderate ultrasonic treatment of aqueous DGR/dichloromethane mixtures caused approximately. Eighty four per cent DGR denaturation. However, the activity recovery of DGR almost amounted to 100% when 2% polyvinyl alcohol (PVA) was addled into the aqueous phase. It was found that NaCl in the external water phase significantly increased DGR encapsulation efficiency. Furthermore, NaCl in the external water phase played a role in determining size and surface morphology of microsphere. In vitro release test showed a burst release of DGR from microspheres, followed by sustained release of 50% total activity over 15 days. In vivo experiments showed that DGR released from microspheres sustained 5 days. Denaturation of DGR within microspheres might be resulted from acidic microclimate. CONCLUSION: The stability of DGR was effectively protected during microencapsulation and a relatively high encapsulation efficiency of DGR was obtained. PLGA microspheres could be an effective carrier for DGR.


Asunto(s)
Proteínas de Escherichia coli/administración & dosificación , Ácido Láctico , Metaloendopeptidasas/administración & dosificación , Ácido Poliglicólico , Polímeros , Animales , Área Bajo la Curva , Portadores de Fármacos , Composición de Medicamentos , Sistemas de Liberación de Medicamentos , Proteínas de Escherichia coli/genética , Proteínas de Escherichia coli/farmacocinética , Variación Genética , Masculino , Metaloendopeptidasas/genética , Metaloendopeptidasas/farmacocinética , Microesferas , Tamaño de la Partícula , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Conejos
9.
Guang Pu Xue Yu Guang Pu Fen Xi ; 26(7): 1209-12, 2006 Jul.
Artículo en Zh | MEDLINE | ID: mdl-17020023

RESUMEN

The secondary structure of a staphylokinase variant (K35R, DGR) encapsulated in poly (lactic-co-glycolic acid) (PLGA) microspheres was quantitatively examined by Fourier transform infrared (FTIR) spectroscopy. Resolution enhancement technique and Fourier deconvolution were combined with band with curve-fitting procedures to quantitate the spectral information from the amide I bands. Nine component bands were found under the broad, nearly featureless amide I bands and assigned to alpha-helix, beta-sheet, turn and irregular (random) structures. The changes of bands at 1 651 and 1 623 cm(-1) after encapsulation were discussed.


Asunto(s)
Metaloendopeptidasas/química , Espectroscopía Infrarroja por Transformada de Fourier/métodos , Ácido Láctico/química , Metaloendopeptidasas/genética , Microesferas , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Estructura Secundaria de Proteína
10.
Eur J Pharm Biopharm ; 109: 24-34, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27569030

RESUMEN

In the present study, surface-functionalized, pH-responsive poly(lactic-co-glycolic acid) (PLGA) microparticles were investigated for nasal delivery of hepatitis B surface Antigen (HBsAg). pH-responsive PLGA, chitosan modified PLGA (CS-PLGA), mannan modified PLGA (MN-PLGA), mannan and chitosan co-modified PLGA (MN-CS-PLGA) microparticles were prepared utilizing a double-emulsion method. Antigen was released rapidly from four types of microparticles at pH5.0 and pH 6.0, but slowly released at pH 7.4. Mannan and chitosan surface modification enhanced intracellular microparticle uptake by macrophages. Following intracellular macrophage antigen uptake, antigen release occurred in three different patterns: fast release from PLGA and MN-PLGA microparticles in endosomes/lysosomes, slow release from CS-PLGA microparticles in cytoplasm and a combination of fast release and slow release patterns from MN-CS-PLGA microparticles. Furthermore, chitosan coating modification increased the residence time of CS-PLGA and MN-CS-PLGA microparticles in the nasal cavity. In vivo immunogenicity studies indicated that MN-CS-PLGA microparticles induced stronger humoral and cell-mediated immune responses compared with PLGA, MN-PLGA and CS-PLGA microparticles. These results suggest that surface modification of pH-responsive PLGA microparticles with mannan and chitosan is a promising tool for nasal delivery of HBsAg.


Asunto(s)
Quitosano/química , Portadores de Fármacos/química , Ácido Láctico/química , Mananos/química , Microesferas , Ácido Poliglicólico/química , Vacunas/administración & dosificación , Administración Intranasal , Animales , Antígenos/química , Sistemas de Liberación de Medicamentos , Emulsiones , Endosomas/química , Femenino , Glicoles , Antígenos de Superficie de la Hepatitis B/administración & dosificación , Concentración de Iones de Hidrógeno , Lisosomas/química , Macrófagos/química , Macrófagos/citología , Macrófagos Peritoneales/metabolismo , Ratones , Nanopartículas/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ratas , Ratas Sprague-Dawley , Propiedades de Superficie
11.
Int J Pharm ; 496(2): 332-41, 2015 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-26453785

RESUMEN

The aim of this study was to prepare poly(lactic-co-glycolic acid) (PLGA) microspheres containing hepatitis B virus surface antigen (HBsAg) using human serum albumin (HSA) as a stabilizer. Lyophilization and emulsification of HBsAg solution with dichloromethane caused a considerable loss of HBsAg antigenicity. Thus, the effects of HSA and trehalose on HBsAg recovery during lyophilization and emulsification were investigated. Adding HSA to HBsAg solutions significantly improved antigen recovery to >90% during lyophilization and emulsification. The effects of co-encapsulated HSA on the characteristics of the PLGA microspheres and stability of HBsAg released from the microspheres were also investigated. The in vitro release test showed that HBsAg was released from the PLGA microspheres continuously over seventy days. A large amount of released HBsAg was inactive without co-encapsulation of HSA. On the contrary, with HSA co-encapsulation, the released HBsAg retained approximately 90% of its antigenicity. The single injection of the HBsAg-HSA-loaded PLGA microspheres in rats resulted in higher anti-HBsAg IgG and Th1 cytokine levels than the single injection of the HBsAg-loaded microspheres or two injections of the conventional aluminum-adjuvanted HBsAg vaccine. Based on these findings, the HBsAg-HSA-loaded PLGA microspheres could be an effective carrier for HBsAg and form a promising depot system.


Asunto(s)
Excipientes/química , Antígenos de Superficie de la Hepatitis B/química , Antígenos de Superficie de la Hepatitis B/inmunología , Ácido Láctico/química , Microesferas , Ácido Poliglicólico/química , Albúmina Sérica/química , Animales , Células CHO , Cricetinae , Cricetulus , Citocinas/inmunología , Citocinas/metabolismo , Femenino , Humanos , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ratas , Ratas Sprague-Dawley
12.
Int J Pharm ; 416(1): 69-76, 2011 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-21699969

RESUMEN

The aim of this study was to prepare recombinant human erythropoietin (rhEPO) loaded poly(lactic-co-glycolic acid) (PLGA) microspheres using human serum albumin (HSA) as a stabilizer. Prior to encapsulation, the rhEPO-HSA mixture microparticles were fabricated using a modified freezing-induced phase separation method. The microparticles were subsequently encapsulated into PLGA microspheres. Process optimization revealed that the polymer concentration in the organic phase and the sodium chloride (NaCl) concentration in the outer water phase of the s/o/w emulsion played critical roles in determining the properties of the resultant microspheres. An in vitro release test showed that rhEPO was released from PLGA microspheres in a sustained manner up to 30 days. A single injection of rhEPO-loaded PLGA microspheres in Sprague-Dawley rats resulted in elevated hemoglobin and red blood cell concentrations for about 33 days. The stability of the rhEPO within the PLGA microspheres was systematically investigated by size-exclusion high-performance liquid chromatography (SEC-HPLC), SDS-PAGE, western blot and in vivo biological activity assay. The stability of rhEPO released from rhEPO-loaded microspheres was also examined by western blot. The results suggested that the integrity of rhEPO was successfully protected during the encapsulation process and the release period from polymeric matrices.


Asunto(s)
Composición de Medicamentos/métodos , Estabilidad de Medicamentos , Eritropoyetina/química , Ácido Láctico/química , Microesferas , Ácido Poliglicólico/química , Albúmina Sérica/química , Animales , Emulsiones/administración & dosificación , Emulsiones/síntesis química , Emulsiones/química , Recuento de Eritrocitos/estadística & datos numéricos , Eritropoyetina/farmacología , Excipientes/química , Hemoglobinas/efectos de los fármacos , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Tamaño de la Partícula , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ratas , Ratas Sprague-Dawley
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA